On February 1, 2024, ArteraAI, developer of multimodal artificial intelligence (MMAI) based predictive and prognostic cancer tests, announced it has secured an additional $20 million in capital fueled by several prominent large investment funds. Less than a year ago, ArteraAI emerged from stealth mode with an initial funding of $90 million. Since then, the company has made significant strides, obtaining a Medicare payment rate, growing distribution, and establishing a solid foundation for international expansion through strategic global partnerships to continue its research.

Wilson Sonsini Goodrich & Rosati has served as counsel to ArteraAI since its incorporation. The Wilson Sonsini team that advised ArteraAI on this funding transaction includes:

Corporate
Andrew Hoffman
Jocqui Kaup
Jun Hyung Lee
Rachita Chatter

National Security
Stephen Heifetz
Jonathan Davey

Technology Transactions
Andrew Poling

Privacy and Cybersecurity
Matthew Staples
Hale Melnick
Michael O’Brien

For more information, please see ArteraAI’s press release.